Achaogen grabs $72M from IPO

The antibiotics developer Achaogen raised $72 million from its IPO. The biotech sold 6 million shares at $12 a share, on the low end of its $12 to $14 share. Renaissance Capital reports that the company's insiders--who had said they were willing to buy up to 25% of the shares--did not participate in the offering. Shares of South San Francisco-based Achaogen will trade as AKAO and the biotech emerges with a market cap of $211 million. This year's Q1 biotech IPOs continue to deliver cash to the sector, following up on the big boom of 2013. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.